MorphoSys, immatics deal

The companies partnered to develop antibodies against undisclosed cancer targets recognized by T cells. MorphoSys will gain access to an undisclosed number of immatics’ tumor-associated peptides (TUMAPs), which MorphoSys will use to develop antibodies to treat solid and hematological cancers. ...